Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.
3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.
12 per fully diluted share in the third quarter of 2024 Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023 Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.
S. Food and Drug Administration Enrollment completed in NEXUS TRIOMPHE clinical trial Received regulatory approval from the National Medical Products Administration (NMPA) to commercialize BioGlue Surgical Adhesive in China . Commercialization expected in the second half of 2025.
ATLANTA , Nov. 7, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2024 .
"We continued our strong financial performance through the third quarter as our team delivered revenue growth consistent with our expectations while executing on several initiatives designed to drive long-term profitable growth with our expanding, clinically differentiated product portfolio. Revenue growth in the third quarter was driven by year-over-year growth in On.
